Pegaspargase Rechallenge Following Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 16‐001
Pediatric Blood & Cancer · 2026-10 · 73 (10)
DOI: 10.1002/1545-5017.70581 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 11.08.2026. Verfasst von Melissa A Burns und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Asparaginase, Polyethylene Glycols, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug Hypersensitivity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Servier Pharmaceuticals, Dana-Farber Cancer Institute.
Abstract (Originalsprache)
Hypersensitivity reactions with pegylated Escherichia coli –derived asparaginase formulations are frequent and can complicate delivery of intended therapy for patients with acute lymphoblastic leukemia (ALL). On DFCI 16‐001, which enrolled patients aged 1–21 years with newly diagnosed ALL, we piloted pegaspargase rechallenge after Grade 2 hypersensitivity reaction, including premedication and serum asparaginase activity (SAA) assessment. Among those who underwent rechallenge, the rechallenge dose was successfully administered (without reaction and with adequate SAA) in 41.3% of patients. This approach reduces the number of patients requiring switch to alternative asparaginase formulations, which have had limited availability and require frequent dosing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Division of Pediatric Hematology/Oncology, Rutgers Cancer Institute; Robert Wood Johnson School of Medicine, New Brunswick, New Jersey, USA.
- Division of Pediatric Hematology/Oncology, Children's Hospital at Montefiore, Bronx, New York, USA.
- Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Columbia University Irving Medical Center, New York, New York, USA.
ORCID-Profile: Andrew E Place, Thai Hoa Tran, Jennifer J G Welch
Förderung
- Servier Pharmaceuticals
- Dana-Farber Cancer Institute
Zitieren
APA
Burns, M. A., Flamand, Y., Keating, J., Koch, V., Cronholm, S. M., Hunt, S. K., Cole, P. D., Gennarini, L. M., Hijiya, N., Kahn, J. M., Kelly, K. M., Michon, B., Neuberg, D. S., Place, A. E., Laverdière, C., Tran, T. H., Théorêt, Y., Welch, J. J. G., Sallan, S. E., …, & Vrooman, L. M. (2026). Pegaspargase Rechallenge Following Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 16‐001. Pediatric Blood & Cancer, 73(10). https://doi.org/10.1002/1545-5017.70581
Vancouver
Burns MA, Flamand Y, Keating J, Koch V, Cronholm SM, Hunt SK, et al. Pegaspargase Rechallenge Following Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 16‐001. Pediatric Blood & Cancer. 2026;73(10). doi:10.1002/1545-5017.70581
BibTeX
@article{Burns2026,
author = {Burns, Melissa A and Flamand, Yael and Keating, Julia and Koch, Victoria and Cronholm, Sarah M and Hunt, Sarah K and Cole, Peter D and Gennarini, Lisa M and Hijiya, Nobuko and Kahn, Justine M and Kelly, Kara M and Michon, Bruno and Neuberg, Donna S and Place, Andrew E and Laverdière, Caroline and Tran, Thai Hoa and Théorêt, Yves and Welch, Jennifer J G and Sallan, Stephen E and Silverman, Lewis B and Vrooman, Lynda M},
title = {Pegaspargase Rechallenge Following Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 16‐001},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {10},
doi = {10.1002/1545-5017.70581}
}
EUVIMED